Antiviral effects of interferon-β are enhanced in the absence of the translational suppressor 4E-BP1 in myocarditis induced by Coxsackievirus B3

Antiviral Therapy

Volumn 16, Issue 4, 2011, Pages 577-584

  Burke, J Daniel ^a,b   Sonenberg, Nahum ^c   Platanias, Leonidas C ^d,e   Fish, Eleanor N ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d NORTHWESTERN UNIVERSITY   (United States)

^e JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA4 INTERFERON; BETA INTERFERON; INITIATION FACTOR 4E BINDING PROTEIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS B3; COXSACKIE VIRUS INFECTION; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; DRUG TARGETING; EMBRYO CELL; FIBROBLAST; HEART; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; INFLAMMATORY INFILTRATE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TRANSLATION REGULATION; VIRUS LOAD; VIRUS MYOCARDITIS;

ANIMALS; ANTIVIRAL AGENTS; CARRIER PROTEINS; CELLS, CULTURED; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS B, HUMAN; FIBROBLASTS; HELA CELLS; HUMANS; INTERFERON-BETA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDITIS; PHOSPHOPROTEINS;

EID: 79959395465     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1752     Document Type: Article

References (38)

1. Rose NR, Čiháková D, Barin JG. Mechanisms underlying myocarditis. Drug Discov Today Dis Mech 2006; 3:207-212. (Pubitemid 44356302)
2. Gupta S, Markham DW, Drazner MH, Mammen PPA. Fulminant myocarditis. Nat Clin Pract Cardiovasc Med 2008; 5:693-706.
3. Ellis CR, Di Salvo T. Myocarditis: basic and clinical aspects. Cardiol Rev 2007; 15:170-177. (Pubitemid 46956452)
4. Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation 2001; 104:1076-1082. (Pubitemid 32803888)
5. Kühl U, Pauschinger M, Schwimmbeck PL, et al. Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003; 107:2793-2798. (Pubitemid 36705988)
6. Bowles NE, Ni J, Kearney DL, Pauschinger M, et al. Detection of viruses in myocardial tissues by polymerase chain reaction: evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 2003; 42:466-472. (Pubitemid 36951713)
7. Kim KS, Hufnagel G, Chapman NM, Tracy S. The group B coxsackieviruses and myocarditis. Rev Med Virol 2001; 11:355-368. (Pubitemid 34024254)
8. Tracy S, Chapman NM, McManus BM, Pallansch MA, Beck MA, Carstens J. A molecular and serologic evaluation of enteroviral involvement in human myocarditis. J Mol Cell Cardiol 1990; 22:403-414. (Pubitemid 20195700)
9. Kühl U, Pauschinger M, Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with 'idiopathic' left ventricular dysfunction. Circulation 2005; 111:887-893.
10. Kühl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005; 112:1965-1970. (Pubitemid 41377415)
11. Stewart MJ, Smoak K, Blum MA, Sherry B. Basal and reovirus-induced beta interferon (IFN-β) and IFN-β-stimulated gene expression are cell type specific in the cardiac protective response. J Virol 2005; 79:2979-2987. (Pubitemid 40270577)
12. Zurney J, Howard KE, Sherry B. Basal expression levels of IFNAR and Jak-STAT components are determinants of cell-type-specific differences in cardiac antiviral responses. J Virol 2007; 81:13668-13680. (Pubitemid 350247860)
13. Richtsteiger R, Henke-Gendo C, Schmidtke M, Harste G, Heim A. Quantitative multiplex real-time PCR for the sensitive detection of interferon β gene induction and viral suppression of interferon β expression. Cytokine 2003; 24:190-200. (Pubitemid 37330121)
14. Kerekatte V, Keiper BD, Badorff C, Cai A, Knowlton KU, Rhoads RE. Cleavage of poly(A)-binding protein by coxsackievirus 2A protease in vitro and in vivo: another mechanism for host protein synthesis shutoff? J Virol 1999; 73:709-717. (Pubitemid 28565416)
15. Joachims M, Van Breugel PC, Lloyd RE. Cleavage of poly(A)-binding protein by enterovirus proteases concurrent with inhibition of translation in vitro. J Virol 1999; 73:718-727. (Pubitemid 28565417)
16. Sommergruber W, Ahorn H, Klump H, et al. 2A proteinases of coxsackie- and rhinovirus cleave peptides derived from elF-4γ via a common recognition motif. Virology 1994; 198:741-745.
17. Liebig HD, Ziegler E, Yan R, et al. Purification of two picornaviral 2A proteinases: interaction with eIF-4γ and influence on in vitro translation. Biochemistry 1993; 32:7581-7588. (Pubitemid 23232335)
18. Lamphear BJ, Yan R, Yang F, et al. Mapping the cleavage site in protein synthesis initiation factor eIF-4γ of the 2A proteases from human coxsackievirus and rhinovirus. J Biol Chem 1993; 268:19200-19203. (Pubitemid 23270688)
19. Esfandiarei M, Luo H, Yanagawa B, et al. Protein kinase B/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent. J Virol 2004; 78:4289-4298. (Pubitemid 38437232)
20. Cornell CT, Kiosses WB, Harkins S, Whitton JL. Inhibition of protein trafficking by coxsackievirus B3: Multiple viral proteins target a single organelle. J Virol 2006; 80:6637-6647. (Pubitemid 43927466)
21. Cornell CT, Kiosses WB, Harkins S, Whitton JL. Coxsackievirus B3 proteins directionally complement each other to downregulate surface major histocompatibility complex class I. J Virol 2007; 81:6785-6797. (Pubitemid 46986615)
22. Dodd DA, Giddings THJ, Kirkegaard K. Poliovirus 3A protein limits interleukin-6 (IL-6), IL-8, and beta interferon secretion during viral infection. J Virol 2001; 75:8158-8165. (Pubitemid 32743688)
23. Kaur S, Lal L, Sassano A, et al. Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem 2007; 282:1757-1768. (Pubitemid 47076718)
24. Deonarain R, Cerullo D, Fuse K, Liu PP, Fish EN. Protective role for interferon-beta in coxsackievirus B3 infection. Circulation 2004; 110:3540-3543. (Pubitemid 39612568)
25. Wang YX, Da Cunha V, Vincelette J, et al. Antiviral and myocyte protective effects of murine interferon-β and -α2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice. Am J Physiol Heart Circ Physiol 2007; 293:H69-H76. (Pubitemid 47105060)
26. Padalko E, Nuyens D, De Palma A, et al. The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis. Antimicrob Agents Chemother 2004; 48:267-274. (Pubitemid 38040207)
27. Matsumori A, Tomioka N, Kawai C. Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice. Am Heart J 1988; 115:1229-1232.
28. Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007; 6:975-990. (Pubitemid 350201788)
29. Parmar S, Platanias LC. Interferons: Mechanisms of action and clinical applications. Curr Opin Oncol 2003; 15:431-439. (Pubitemid 38147038)
30. Lekmine F, Sassano A, Uddin S, et al. Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. Exp Cell Res 2004; 295:173-182. (Pubitemid 38407355)
31. Lekmine F, Uddin S, Sassano A, et al. Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J Biol Chem 2003; 278:27772-27780. (Pubitemid 36899968)
32. Guiducci C, Ghirelli C, Marloie-Provost MA, et al. PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J Exp Med 2008; 205:315-322. (Pubitemid 351281597)
33. Cao W, Manicassamy S, Tang H, et al. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTORp70S6K pathway. Nat Immunol 2008; 9:1157-1164.
34. Schmitz F, Heit A, Dreher S, et al. Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur J Immunol 2008; 38:2981-2992.
35. Colina R, Costa-Mattioli M, Dowling RJ, et al. Translational control of the innate immune response through IRF-7. Nature 2008; 452:323-328. (Pubitemid 351430792)
36. + T-cell infiltration during autoimmune myocarditis. Immunol Cell Biol 2004; 82:119-126.
37. + T lymphocytes in coxsackievirus B3-induced myocarditis. J Virol 1995; 69:6720-6728.
38. Opavsky MA, Penninger J, Aitken K, et al. Susceptibility to myocarditis is dependent on the response of αβ T lymphocytes to coxsackieviral infection. Circ Res 1999; 85:551-558. (Pubitemid 29431956)